Skip to main content
Back
XERS logo

Xeris Biopharma Holdings, Inc.

Data quality: 100%
XERS
NASDAQ Healthcare Biotechnology
$5.30
▲ $0.01 (0.19%)
Mkt Cap: 913.88M
Day Range
$5.25 $5.48
52-Week Range
$3.81 $10.08
Volume
2,341,948
50D / 200D Avg
$6.75 / $6.88
Prev Close
$5.29

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (631 peers)

Metric Stock Sector Median
P/E 1649.6 0.3
P/B 66.8 3.0
ROE % — 3.7
Net Margin % 0.2 3.8
Rev Growth 5Y % 55.8 10.0
D/E 2.8 0.2

Analyst Price Target

Hold
$13.50 +154.7%
Low: $9.00 High: $18.00
Forward P/E
44.17
Forward EPS
$0.12
EPS Growth (est.)
+0.0%
Est. Revenue
384.03M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1.09
$1.06 – $1.14
 701.45M 1
FY2029 $0.89
$0.87 – $0.93
 607.63M 1
FY2028 $0.59
$0.38 – $0.82
 540.02M 5

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-02 $0.02 $0.06 +191.0%
2025-11-06 $0.01 $0.00 -65.0%
2025-08-07 -$0.03 -$0.01 +66.7%
2025-05-08 -$0.07 -$0.06 +14.3%
2025-03-06 -$0.08 -$0.03 +62.5%
2024-11-08 -$0.09 -$0.06 +33.3%
2024-08-08 -$0.11 -$0.10 +9.1%
2024-05-09 -$0.12 -$0.14 -16.7%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Key Takeaways

Revenue grew 55.75% annually over 5 years — strong growth
Debt/Equity of 2.76 — high leverage
Generating 27.93M in free cash flow
P/E of 1649.61 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 12.03%
Cash machine — converts 5041.52% of earnings into free cash flow

Growth

Revenue Growth (5Y)
55.75%
Revenue (1Y)43.72%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC36.29%
Net Margin0.19%
Op. Margin8.53%

Safety

Debt / Equity
2.76
Current Ratio2.19
Interest Coverage0.86

Valuation

P/E Ratio
1649.61
Forward P/E44.17
P/B Ratio66.76
EV/EBITDA33.76
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 43.72% Revenue Growth (3Y) 33.43%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 55.75% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 291.85M Net Income (TTM) 554,000.0
ROE N/A ROA 0.14%
Gross Margin 81.70% Operating Margin 8.53%
Net Margin 0.19% Free Cash Flow (TTM) 27.93M
ROIC 36.29% FCF Growth (3Y) N/A
Safety
Debt / Equity 2.76 Current Ratio 2.19
Interest Coverage 0.86
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 1649.61 Forward P/E 44.17
P/B Ratio 66.76 P/S Ratio 3.13
PEG Ratio -22.52 Forward PEG N/A
EV/EBITDA 33.76 Fwd EV/EBITDA N/A
Forward P/S 2.38 Fwd Earnings Yield 2.26%
FCF Yield 3.06%
Market Cap 913.88M Enterprise Value 840.61M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 291.85M 203.07M 163.91M 110.25M 49.59M
Net Income 554,000.0 -54.84M -62.26M -94.66M -122.73M
EPS (Diluted) 0.00 -0.37 -0.45 -0.70 -1.55
Gross Profit 238.43M 166.24M 135.27M 87.61M 36.27M
Operating Income 24.90M -33.65M -44.01M -81.94M -115.16M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 383.53M 323.06M 322.60M 344.52M 304.36M
Total Liabilities 369.84M 352.68M 329.38M 299.34M 209.13M
Shareholders' Equity 13.69M -29.62M -6.78M 45.19M 95.23M
Total Debt 37.76M 271.45M 229.19M 198.06M 88.07M
Cash & Equivalents 111.04M 71.62M 67.45M 121.97M 67.27M
Current Assets 240.31M 167.66M 156.26M 186.82M 142.60M
Current Liabilities 109.57M 100.44M 95.19M 73.62M 79.04M